A Phase 4 interventional study of Risankizumab and Placebo for Risankizumab in Genital Psoriasis and Scalp Psoriasis, sponsored by AbbVie. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.
Among the 30 studies testing risankizumab in Psoriasis, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 7 in phase 4, and was the 28th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 30 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 30 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 21st largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 in phase 4, and was the 74th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing risankizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored.
Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally.
The study will be broken up into 2 studies by disease location, participants with moderate to severe genital psoriasis (Study-G) and moderate to severe scalp psoriasis (Study-S). In both studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Safety and efficacy data through 22 January 2025 are included in the interim analysis, which was conducted after all participants completed Week 16 of Study-G or Study-S in Period A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate to severe genital psoriasis received placebo for risankizumab subcutaneously at Weeks 0 and 4 during Period A.
Drug: Placebo for Risankizumab
Participants with moderate to severe genital psoriasis received 150 mg of risankizumab subcutaneously at Weeks 0 and 4 during Period A.
Drug: Risankizumab
Participants with moderate to severe scalp psoriasis received placebo for risankizumab subcutaneously at Weeks 0 and 4 during Period A.
Drug: Placebo for Risankizumab
Participants with moderate to severe scalp psoriasis received 150 mg of risankizumab subcutaneously at Weeks 0 and 4 during Period A.
Drug: Risankizumab
Participants with moderate to severe genital psoriasis received placebo for risankizumab during Period A, and 150 mg of risankizumab subcutaneously at Weeks 16, 28, and 40 during Period B.
Drug: Risankizumab
Participants with moderate to severe genital psoriasis received 150 mg of risankizumab subcutaneously during Period A, and continued with this treatment at Weeks 16, 28, and 40 during Period B.
Drug: Risankizumab
Participants with moderate to severe scalp psoriasis received placebo for risankizumab during Period A, and 150 mg of risankizumab subcutaneously at Weeks 16, 28, and 40 during Period B.
Drug: Risankizumab
Participants with moderate to severe scalp psoriasis received 150 mg of risankizumab subcutaneously during Period A, and continued with this treatment at Weeks 16, 28, and 40 during Period B.
Drug: Risankizumab
Subcutaneous injection
Also known as: Skyrizi, ABBV-066
Subcutaneous injection
Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16
The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of psoriatic genital lesions.
Time frame: Week 16
Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16
The scalp IGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The scalp IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. Higher scores indicate more severe disease.
Time frame: Week 16
Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 at Week 16
The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
Time frame: Week 16
Study-G: Percentage of Participants With Achievement of Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 16
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) and has a 1-week recall period. The response options range from 0 (not affected at all) to 3 (very much affected). This gives an overall range of 0 to 30 where lower scores mean better quality of life.
Time frame: Week 16
Study-G: Percentage of Participants With Achievement of Clinically Meaningful (≥ 4-point) Improvement From Baseline on the Genital Psoriasis Itch Numerical Rating Scale (NRS) at Week 16 [Among Participants With a Baseline Score ≥ 4]
The scalp Itch NRS is a self-administered NRS that asks participants to assess their scalp itch on a scale from 0 to 10 where 0 represents no itch and 10 represents worst imaginable itch.
Time frame: Baseline, Week 16
Study-G: Percentage of Participants With Achievement of Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 [Among Participants With a Baseline Score ≥ 2]
The GenPs-SFQ is a patient-reported outcome(s) \[PRO\] measure to evaluate the impact of genital psoriasis symptoms on sexual frequency, using a 1-week recall period. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Each item uses a Likert scale. Respondents are asked to answer the questions based on their psoriasis symptoms in the genital area. Genital area is defined as the labia majora (outer lip), labia minora (inner lip), and perineum (area between vagina and anus) for females; penis, scrotum, and perineum (area between the penis and anus) for males. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with response options ranging from 0 (never) to 4 (always).
Time frame: Baseline, Week 16
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16
PSSI 90 is defined as ≥ 90% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.
Time frame: Baseline, Week 16
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 75 (PSSI 75) at Week 16
PSSI 75 is defined as ≥ 75% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.
Time frame: Baseline, Week 16
Study-S: Change From Baseline in Psoriasis Symptom Scale (PSS) at Week 16
The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe), with total scores, which is the sum of the four item responses, ranging from 0 to 16 and higher scores indicating worse symptoms. Negative changes from Baseline indicate improvement.
Time frame: Baseline, Week 16
Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index (PSSI 100) at Week 16
PSSI 100 is defined as ≥ 100% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.
Time frame: Baseline, Week 16
Study-S: Percentage of Participants With Achievement of Psoriasis Symptom Scale (PSS) of 0 at Week 16
The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe).
Time frame: Week 16
This study was conducted at 30 sites in the United States with a total of 214 participants and was initiated in August 2023. Adults with with moderate to severe genital (Study-G) or scalp (Study-S) psoriasis were eligible.
| Milestone | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Study-G Placebo/Risankizumab (Period B) | Study-G Risankizumab/Risankizumab (Period B) | Study-S Placebo/Risankizumab (Period B) | Study-S Risankizumab/Risankizumab (Period B) |
|---|---|---|---|---|---|---|---|---|
| Started | 54 | 55 | 54 | 51 | 0 | 0 | 0 | 0 |
| Completed | 53 | 54 | 49 | 51 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Study-G Placebo/Risankizumab (Period B) | Study-G Risankizumab/Risankizumab (Period B) | Study-S Placebo/Risankizumab (Period B) | Study-S Risankizumab/Risankizumab (Period B) |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 53 | 54 | 48 | 51 |
| Completed | 0 | 0 | 0 | 0 | 11 | 9 | 17 | 19 |
| Not completed | 0 | 0 | 0 | 0 | 42 | 45 | 31 | 32 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Ongoing in period b | 0 | 0 | 0 | 0 | 40 | 45 | 27 | 25 |
The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of psoriatic genital lesions.
| percentage of participants | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) |
|---|---|---|
| Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 | 13.0 | 69.1 |
The scalp IGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The scalp IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. Higher scores indicate more severe disease.
| percentage of participants | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) |
|---|---|---|
| Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16 | 13.0 (4.0 to 21.9) | 60.8 (47.4 to 74.2) |
The sPGA-G is a 6-point score ranging from 0 to 5, with a higher score indicating greater severity, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions.
| percentage of participants | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) |
|---|---|---|
| Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 at Week 16 | 5.6 (0.0 to 11.7) | 50.9 (37.7 to 64.1) |
The DLQI is a self-administered, 10-question questionnaire covering 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) and has a 1-week recall period. The response options range from 0 (not affected at all) to 3 (very much affected). This gives an overall range of 0 to 30 where lower scores mean better quality of life.
| percentage of participants | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) |
|---|---|---|
| Study-G: Percentage of Participants With Achievement of Dermatology Life Quality Index (DLQI) of 0 or 1 at Week 16 | 3.7 (0.0 to 8.7) | 60.0 (47.1 to 72.9) |
The scalp Itch NRS is a self-administered NRS that asks participants to assess their scalp itch on a scale from 0 to 10 where 0 represents no itch and 10 represents worst imaginable itch.
| percentage of participants | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) |
|---|---|---|
| Study-G: Percentage of Participants With Achievement of Clinically Meaningful (≥ 4-point) Improvement From Baseline on the Genital Psoriasis Itch Numerical Rating Scale (NRS) at Week 16 [Among Participants With a Baseline Score ≥ 4] | 6.7 (0.0 to 14.0) | 48.8 (33.5 to 64.1) |
The GenPs-SFQ is a patient-reported outcome(s) \[PRO\] measure to evaluate the impact of genital psoriasis symptoms on sexual frequency, using a 1-week recall period. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Each item uses a Likert scale. Respondents are asked to answer the questions based on their psoriasis symptoms in the genital area. Genital area is defined as the labia majora (outer lip), labia minora (inner lip), and perineum (area between vagina and anus) for females; penis, scrotum, and perineum (area between the penis and anus) for males. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with response options ranging from 0 (never) to 4 (always).
| percentage of participants | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) |
|---|---|---|
| Study-G: Percentage of Participants With Achievement of Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16 [Among Participants With a Baseline Score ≥ 2] | 21.9 (7.6 to 36.2) | 71.0 (55.0 to 86.9) |
PSSI 90 is defined as ≥ 90% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) |
|---|---|---|
| Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 90 (PSSI 90) at Week 16 | 13.0 (4.0 to 21.9) | 52.9 (39.2 to 66.6) |
PSSI 75 is defined as ≥ 75% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) |
|---|---|---|
| Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index 75 (PSSI 75) at Week 16 | 22.2 (11.1 to 33.3) | 74.5 (62.5 to 86.5) |
The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe), with total scores, which is the sum of the four item responses, ranging from 0 to 16 and higher scores indicating worse symptoms. Negative changes from Baseline indicate improvement.
| units on a scale | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) |
|---|---|---|
| Study-S: Change From Baseline in Psoriasis Symptom Scale (PSS) at Week 16 | -1.036 (-2.249 to 0.178) | -6.013 (-7.283 to -4.743) |
PSSI 100 is defined as ≥ 100% improvement from Baseline in PSSI. The physician will assess the severity of scalp psoriasis using the PSSI, which consists of an assessment of erythema, induration, and desquamation on a scale from 0 (none) to 4 (very severe) and the percentage of scalp involved on a scale from 1 (\<10% of scalp involved) to 6 (90 to 100% of scalp involved). The composite score is calculated as the sum of the scores for erythema, induration and desquamation multiplied by the score recorded for the extent of scalp area involved. The PSSI ranges from 0 to 72, with higher scores indicating more severe disease.
| percentage of participants | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) |
|---|---|---|
| Study-S: Percentage of Participants With Achievement of Psoriasis Scalp Severity Index (PSSI 100) at Week 16 | 13.0 (4.0 to 21.9) | 45.1 (31.4 to 58.8) |
The PSS is a 4-item PRO instrument that assesses the severity of psoriasis symptoms in participants with moderate to severe psoriasis, using a recall period of 1 day. The symptoms include pain, redness, itching and burning from psoriasis. Current symptom severity is assessed using a 5-point Likert-type scale ranging from 0 (none) to 4 (very severe).
| percentage of participants | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) |
|---|---|---|
| Study-S: Percentage of Participants With Achievement of Psoriasis Symptom Scale (PSS) of 0 at Week 16 | 3.7 (0.0 to 8.7) | 13.7 (4.3 to 23.2) |
Collected over All-cause mortality and adverse event tables include events reported from time informed consent was signed through 22 January 2025, after all participants completed Week 16 of Study-G or Study-S in Period A. Median time on follow-up in Period A was 112 days for all groups. Median time on follow-up in Period B ranged from 136 to 142 days in Study-G and 260 to 285 days in Study-S.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study-G Placebo (Period A) | 0/54 (0%) | 1/54 (1.9%) | 8/54 (14.8%) |
| Study-G Risankizumab (Period A) | 0/55 (0%) | 1/55 (1.8%) | 8/55 (14.5%) |
| Study-S Placebo (Period A) | 0/54 (0%) | 1/54 (1.9%) | 7/54 (13%) |
| Study-S Risankizumab (Period A) | 0/51 (0%) | 3/51 (5.9%) | 9/51 (17.6%) |
| Study-G Placebo/Risankizumab (Period B) | 0/53 (0%) | 1/53 (1.9%) | 8/53 (15.1%) |
| Study-G Risankizumab/Risankizumab (Period B) | 0/54 (0%) | 1/54 (1.9%) | 8/54 (14.8%) |
| Study-S Placebo/Risankizumab (Period B) | 0/48 (0%) | 1/48 (2.1%) | 7/48 (14.6%) |
| Study-S Risankizumab/Risankizumab (Period B) | 0/51 (0%) | 3/51 (5.9%) | 9/51 (17.6%) |
| Event | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Study-G Placebo/Risankizumab (Period B) | Study-G Risankizumab/Risankizumab (Period B) | Study-S Placebo/Risankizumab (Period B) | Study-S Risankizumab/Risankizumab (Period B) |
|---|---|---|---|---|---|---|---|---|
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/54 | 0/55 | 1/54 | 0/51 | 0/53 | 0/54 | 1/48 | 0/51 |
| ANGINA UNSTABLECardiac disorders | 0/54 | 0/55 | 1/54 | 0/51 | 0/53 | 0/54 | 1/48 | 0/51 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/54 | 0/55 | 0/54 | 1/51 | 0/53 | 0/54 | 0/48 | 1/51 |
| CELLULITISInfections and infestations | 0/54 | 1/55 | 0/54 | 1/51 | 0/53 | 1/54 | 0/48 | 1/51 |
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 0/54 | 0/55 | 0/54 | 1/51 | 0/53 | 0/54 | 0/48 | 1/51 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 1/54 | 0/55 | 0/54 | 0/51 | 1/53 | 0/54 | 0/48 | 0/51 |
| Event | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Study-G Placebo/Risankizumab (Period B) | Study-G Risankizumab/Risankizumab (Period B) | Study-S Placebo/Risankizumab (Period B) | Study-S Risankizumab/Risankizumab (Period B) |
|---|---|---|---|---|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/54 | 4/55 | 2/54 | 6/51 | 2/53 | 4/54 | 2/48 | 6/51 |
| COVID-19Infections and infestations | 2/54 | 2/55 | 2/54 | 4/51 | 2/53 | 2/54 | 2/48 | 4/51 |
| NASOPHARYNGITISInfections and infestations | 2/54 | 2/55 | 3/54 | 1/51 | 2/53 | 2/54 | 3/48 | 1/51 |
| DEPRESSIONPsychiatric disorders | 3/54 | 0/55 | 0/54 | 0/51 | 3/53 | 0/54 | 0/48 | 0/51 |
Intent-to-Treat Population (ITT): ITT\_G (participants randomized in Study-G); ITT\_S (participants randomized in Study-S)
| Age, Continuous(years) | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Total |
|---|---|---|---|---|---|
| Mean | 46.3 ± 15.73 | 45.3 ± 14.97 | 46.7 ± 14.23 | 46.0 ± 14.75 | 45.6 ± 14.80 |
| Sex: Female, Male(Participants) | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Total |
|---|---|---|---|---|---|
| Female | 22 | 16 | 22 | 24 | 84 |
| Male | 32 | 39 | 32 | 27 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 17 | 15 | 26 | 12 | 70 |
| Not Hispanic or Latino | 37 | 40 | 28 | 39 | 144 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Study-G Placebo (Period A) | Study-G Risankizumab (Period A) | Study-S Placebo (Period A) | Study-S Risankizumab (Period A) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 1 | 3 | 3 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 2 | 0 | 4 | 4 | 10 |
| White | 50 | 48 | 43 | 44 | 185 |
| More than one race | 1 | 2 | 2 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Aug 2023 to primary completion in Jan 2025, 17 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 17 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab